Cancer immunotherapy · Cell Rep Med · 2026
Public plan’s main goal: tumor shrinkage. The paper’s main goal: safety. It never mentions the difference.
Each goal’s place in the trial’s public plan and in the paper
The paper says
In an early cancer trial, 25 people got their own immune cells, multiplied in a lab and injected inside the skull, plus a drug. The paper’s main goal: safety, measured as side effects serious enough to stop raising the dose. None were seen.
Its own data show
The public plan’s one main goal: tumor shrinkage at 24 months. The paper makes shrinkage secondary or exploratory and uses each patient’s best scan, not 24 months: tumors shrank enough to count in 2 of 17 assessed. Counting all 25, as the plan’s wording implies, gives 2 of 25 (8%), a figure the paper omits.
Trials post their main goal in a public registry so readers can check the paper reports the planned result. Safety as the main goal is normal for a first test in people. The problem: the paper never says its plan named another goal, and its summary leaves that goal’s result out, saying instead the disease seemed to hold steady.